Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pipeline Potential | Explore Pfizer's strategic focus on oncology and weight management, with promising developments in SSGJ-707 for non-small cell lung cancer treatment |
Financial Health | Discover Pfizer's robust financials, including a 74% gross profit margin and 6.8% dividend yield, with maintained revenue guidance of $61-64 billion for FY2025 |
Market Positioning | Analysts view Pfizer as undervalued compared to peers, with price targets ranging from $24 to $36, reflecting potential for growth and margin expansion |
Strategic Challenges | Learn about Pfizer's response to setbacks in clinical trials and its ambitious cost optimization strategy, aiming for $4.5 billion in net savings by 2025 |
Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
---|---|---|---|---|
P/E Ratio | 13.2x | −6.1x | −0.7x | |
PEG Ratio | 0.03 | 0.01 | 0.00 | |
Price/Book | 1.6x | 3.3x | 2.6x | |
Price / LTM Sales | 2.2x | 5.7x | 3.4x | |
Upside (Analyst Target) | 16.3% | 37.9% | 39.1% | |
Fair Value Upside | Unlock | 6.5% | 5.3% | Unlock |